Showing results (71-80 of 114) with videos related to
Sort By:
Pageof 12
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.European Journal of Cancer (Oxford, England : 1990)|January 3, 2016
Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?Damien Pouessel, Sylvie Chevret, Frédéric Rolland, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.BJUI Compass|July 21, 2025
Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patientsIlfad Blazevic, Aude Fléchon, Géraldine Pignot, et al.Clinical Genitourinary Cancer|October 4, 2018
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG StudyAline Guillot, Charlotte Joly, Philippe Barthélémy, et al.International Journal of Surgical Pathology|April 25, 2022
The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory AnalysisLaura S Mertens, Francesco Claps, Roman Mayr, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III TrialKarim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.The Oncologist|May 17, 2023
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I ResultsDamien Pouessel, Soléakhéna Ken, Valérie Gouaze-Andersson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 TrialNadine Houédé, Thierry Chevallier, François Audenet, et al.Pageof 12